Akorn enters premix contract
BUFFALO GROVE -- Akorn Inc. announced on Thursday that it signed a five-year supply agreement with Fresenius Kabi for a premix product. Premix medications are ready to use intravenous drug products, which eliminate compounding steps in the pharmacy or at the point of care. Buffalo Grove-based Akorn will be responsible for development, marketing and distribution of the undisclosed product. Fresenius Kabi will make it in Halden, Norway.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.